期刊文献+

左氧氟沙星雷贝拉唑阿莫西林根除幽门螺旋杆菌疗效分析 被引量:2

下载PDF
导出
摘要 目的:观察含左氧氟沙星、雷贝拉唑、阿莫西林三联疗法根除幽门螺旋杆菌(H.pylori,HP)的疗效。方法:将87例HP阳性的消化性溃疡患者随机分成治疗组与对照组,治疗组45例,对照组42例。治疗组采用左氧氟沙星、雷贝拉唑、阿莫西林治疗。对照组采用甲硝唑、雷贝拉唑、阿莫西林治疗。治疗结束后4周,复查胃镜并检测HP,记录患者溃疡愈合率及HP根除情况。结果:87例均顺利完成治疗方案,治疗组与对照组HP根除率分别为91.1%、83.3%,差异有统计学意义(P<0.05);溃疡愈合率分别为88.9%、85.8%,差异无统计学意义(P>0.05)。结论:采用左氧氟沙星、雷贝拉唑、阿莫西林三联疗法治疗消化性溃疡患者,有良好HP根除率,是安全有效的HP根除方案。
作者 易胜阳
机构地区 北海
出处 《现代医药卫生》 2011年第19期2920-2921,共2页 Journal of Modern Medicine & Health
  • 相关文献

参考文献12

  • 1Chey WD, Wong BC.American College of Gastroenterology guideline on the management of Helicobacter pylori infection[J].Am J Gastroenterol, 2007,102 : 1808.
  • 2Vakil N.H-pylori treatment:new wine in old bottles[J].Am J Gastroenterol, 2009,4 : 26.
  • 3中华医学会消化病学分会幽门螺杆菌学组.全国幽门螺杆菌科研协作组,中国幽门螺杆菌耐药状况以及耐药对治疗的影响.胃肠病学,2007,12:525-525.
  • 4Di Caro S, Zocco MA, Cremonini F ,et al.Levofloxaein based regimen-for the eradication of Helicobacter pylori[J].Eur J Gastmenterol Hepatol, 2002,14 : 1309.
  • 5Pe F, Festa V, Merla A, et al.Randomized study of different second-line therapies for Helicobacter pylori infection after failure of the standard Maastricht triple therapy[J].Aliment Phannaeol Ther,2003, 18:815.
  • 6Cammarota G, Martino A ,Pirozzi G,et al.Hig efficacy of 1-week doxycyc-line-and amoxicillin-based quadruple regimen in a culture-guided,thind-line treatment approach for Helicobacter pylori infection[J].Aliment Pharmacol Ther,2004,19:789.
  • 7邹军,杨昭徐,唐明忠,康熙雄.幽门螺杆菌对4种抗菌药物的敏感性检测及意义[J].临床检验杂志,2003,21(4):219-220. 被引量:20
  • 8Kong WX, Wang GX, Lig S.Rabeprazole combination to treat chronic gastritis with HP infection[J].He Nan Medicalinfor-mation,2003,24 :40.
  • 9张喜梅,张振玉.含左氧氟沙星、雷贝拉唑的三联方案治疗幽门螺杆菌94例[J].世界华人消化杂志,2008,16(4):443-445. 被引量:8
  • 10Lykke JA,Langhof-Roos Jens,Sibai BM ,et al.Hypertensive disorders in pregnancy,recurrence in a second pregnancy,and subsequent cardiovaseular events : 10[J].Am J Obstet Gynecol, 2008,199 (6) : S6.

二级参考文献36

  • 1唐丽安,李点玲,张桂英.雷贝拉唑三联5日疗法根除幽门螺杆菌的疗效观察[J].中国现代医学杂志,2005,15(24):3789-3791. 被引量:4
  • 2Georgopoulos S D, Ladas S D, Karatapanis S, et al. Factors that may affect treatment outcome of triple Helicobacter priori eradication therapy with omeprazole, amoxicillin, and clarithromycin [ J ]. Dig Dis Sci, 2000, 45(1):63-67.
  • 3Piccolomini R,Bonavenura G D,Catamo,et al.Comparative eveluation of the E test,agar dilution,and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents[J].J Clin Microbiol,1997,35(7):1842-1846.
  • 4Pfaller M A,Barry A L, Fuchs P C. et al. Levofloxacin disk potency and tentative intexpretive criteria for susceptibility tests[J]. J Clin Microbiol, 1993,31(7):1924-1926.
  • 5van der Wouden E J, Thijs J C, van Zwet A A, et al. Nitrointidazole resistance in Helicobacter pylori[J]. Aliment Pharmaed Ther, 2000, 14 (1):7-14.
  • 6Boyanova L, Stancheva I, Spassova Z, et al. Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia,Bulgaria[J] .J Med Microbiol,2000,49(5):415-418.
  • 7Ducons J A, Sentolaria S, Guirao R, et al. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer[J].Aliment Pharmacol Ther, 1999, 13(6):775-780.
  • 8Yakoob J, Fan X, Hu G,et al. Antibiotic susceptibility of Helicobacter pylori in the Chinese population[J] .J Gastroenterol and Hepatol,2001,16 (9) :981-985.
  • 9Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus on the management of Helicobacterpylori infection. J Gastroenterol Hepatol, 1998,13: 1~12.
  • 10European Helicobacter pylori Study Group. Current European concepts in the management ofHelicobacter pylori infection. The Maastricht Consensus Report. Gut, 1997, 41: 8~13.

共引文献85

同被引文献6

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部